WHO's new guideline supports the use of low-cost second and third-line medications for type 2 diabetes. It also promotes the use of human insulin for controlling blood glucose level in diabetic patients. The new guideline reviewed the newer diabetes medicines and concluded that these medications are more expensive and their benefits are based on weak evidence. These newer diabetic medications are more expensive and create a financial burden on the individual health system.
The WHO core function is to provide a guide to a public health problem but the focus is on low and middle-income countries, where technical expertise and financial resources are often lacking. This approach provides the access to services and medicines for achieving a balance between implementing the best-established standard of care and in resource-limited settings. Earlier WHO reviewed newer second and third-line…
